Cartilage-hair hypoplasia (CHH) or McKusick type metaphyseal chondrodysplasia (MIM No 250250) is a rare autosomal recessive chondrodysplasia with short limbed short stature, hypoplastic hair, and defective immunity and erythropoiesis. The major radiological abnormalities are confined to the metaphyseal regions of the tubular bones. The disease is prevalent among the Old Order Amish in the United States and in the Finnish population. While genealogical data confirm autosomal recessive inheritance, segregation analysis shows a lack of affected persons among both the Amish and Finnish CHH families; this has been interpreted as a possible example of reduced penetrance. The CHH gene was recently assigned to chromosome 9 by linkage analysis, and its localisation refined. This has allowed prenatal diagnosis in four cases.

Clinical description

GROWTH FAILURE

The growth failure has its onset prenatally; the shortness of limbs or stature or both was noticed neonatally in 76% and by the age of 1 year in 98% of 108 Finnish CHH patients. All segments of the limbs are affected. The growth failure is progressive, owing in part to a weak or absent pubertal growth spurt; pubertal maturation is normal. Adult heights range from 103-7 cm to 149-0 cm with medians of 131-1 cm for males and 122-5 cm for females.

The growth failure is disproportionate with a long trunk in relation to the short limbs. The more severe the growth failure, the greater the disproportion. Proportionate short stature has been described in some CHH patients.

Median relative weight is above the normal mean in childhood and is further augmented around puberty; most adult patients are clinically obese. The head circumference is close to normal at all ages.

OTHER CLINICAL FEATURES

The majority of affected persons have sparse, fine, and silky hair; the eyebrows, eyelashes, and body hair are similarly affected. In some patients, however, the hair appears normal. This was observed in 7% of the Finnish CHH patients.

Other clinical features include laxity of ligaments, limited extension of the elbows, increased lumbar lordosis, bowing of the lower limbs, chest deformity (narrow thorax, Harrison's grooves, prominent sternum, or asymmetry), and mild scoliosis (figs 1 and 2).

IMMUNE DEFICIENCY

The defective cellular immunity is characterised by mild to moderate lymphopenia, decreased delayed hypersensitivity, and impaired in vitro responsiveness of lymphocytes to PHA; humoral immunity is usually intact. A few patients with normal immunity or combined immunodeficiency have been reported. Defective cellular immunity results in susceptibility to infections. The infection problems are most pronounced in early childhood but occasionally persist to adult age. Varicella infection has been fatal in a few cases. In the Finnish series impaired in vitro cellular immunity was observed in 88% of the patients. Fifty-six percent had been unusually prone to infections. Six patients (6%) had died of primary infections. On the other hand, 44% of the patients had shown no unusual susceptibility to infections even though deficient cellular immunity had been confirmed in half of them.

The incidence of malignancies is increased as observed in the Finnish series and cases described earlier. Among the Finnish patients the incidence was six out of 108 patients (6%): skin neoplasms in three patients, lymphoma in one patient. Among the Finnish patients the incidence was six out of 108 patients (6%): skin neoplasms in three patients, lymphoma in one, lymphosarcoma in one, and testicular tumour in one patient.

ANAEMIA

Deficient erythrocyte production presents usually as mild macrocytic anaemia in early childhood with spontaneous recovery before adulthood. Occasionally, however, the patients have severe, even fatal, congenital hypoplastic anaemia. Sixty-seven out of 85 Finnish patients (79%) had been anaemic during childhood; in 14 patients (16%) the anaemia had been severe (lowest haemoglobin value 30–75 g/l) with a fatal course in six patients.
Fig. 1  Six CHH patients, front view. Age and absolute and relative values of height (from left to right): (1) 3-6 years, 74-5 cm (-6-8 SD); (2) 3-5 years, 84-3 cm (-4-1 SD); (3) 5-5 years, 94-8 cm (-4-1 SD); (4) 10-2 years, 113-2 cm (-4-7 SD); (5) 15-2 years, 123-9 cm (-6-1 SD); (6) 28-7 years, 134-2 cm (-5-8 SD).

Intestinal manifestations
There have been several descriptions of CHH patients with congenital megacolon (Hirschsprung's disease). The Finnish series included eight patients (7%) with congenital megacolon. These cases clearly indicate increased prevalence of Hirschsprung's disease among CHH patients.

Intestinal malabsorption was suspected in six Amish patients who had diarrhoea and failure to thrive in the first two years of life. However, primary malabsorption was not observed in any of the 108 Finnish CHH patients; instead, gastrointestinal infection was confirmed in two patients with symptoms suggesting malabsorption. These and other reported cases suggest that primary malabsorption is only exceptionally associated with CHH; mimicking symptoms may reflect an underlying gastrointestinal infection.

Orthopaedic problems
Orthopaedic problems in CHH are rare compared with many other chondrodysplasias. Ligamentous laxity and increased lumbar lordosis may cause arthralgic pains in the knees, ankles, or lumbar region of the spine. Bow legs may necessitate corrective osteotomy (in 14% of the Finnish patients).

Radiographic features
The tubular bones are short for age and their metaphyseal ends are flared, scalloped, and irregularly sclerotic, often with cystic areas (fig 3); the epiphyses are less affected. The metaphyseal changes are most pronounced in the knees and ankles; the hips are only mildly affected (fig 4). The metaphyseal irregularities disappear after the closure of the epiphyseal plates but the ends remain somewhat flared and angulated. The spine shows only minor abnormalities: the vertebral bodies are usually normal and caudal widening of the interpediculate distances, though less obvious than normal, is present in most patients (fig 5).

Lumbar lordosis is increased and further ac-

Fig. 2  Six CHH patients, side view. Same patients as in fig 1. Note the variation in the degree of disproportion, hair hypoplasia, lumbar lordosis, and chest deformity.
centuated by a horizontally tilted sacrum (fig 5).

**Differential diagnosis**
Most of the 150 different osteochondrodysplasias result in disproportionate short stature and progressive problems in the joints and spine. The clinical features of CHH resemble those of hypochondroplasia (MIM 14600)\(^1\) which, however, is a dominantly inherited condition and does not present with abnormal hair. It is easily differentiated from CHH by normal metaphyses in childhood skeletal radiographs. Murk Jansen (MIM 156400) and Schmid (MIM 156500) metaphyseal dysplasias are dominantly inherited conditions and result in severe growth failure but patients have normal immunity and erythrogenesis; these are easily distinguished from CHH. Recently, a type X collagen mutation was reported as the cause of Schmid chondrodysplasia.\(^3\) Shwachman-Bodian syndrome (MIM 260400), an autosomal recessive condition with metaphyseal involvement, is associated with pancreatic insufficiency, malabsorption, and leukopenia; the mild skeletal changes are most evident in the proximal femora.

**Epidemiology**
CHH was originally described among the Old Order Amish, a religious isolate in the United States.\(^2\) At least 113 Amish CHH patients have been recognised\(^2\); the incidence is estimated at 1:2-1000 corresponding to a carrier frequency of 1:10. Another accumulation of the disease has been observed among Finns with 120 patients in a population of 5 million; the incidence is estimated at 1:23,000 live births and the carrier frequency at 1:76.\(^4\) The number of diagnosed patients among other populations is low: 13 patients have been reported among the French, eight among the Dutch, seven among the British, and sporadic cases among the Germans, Danes, Italians, French, Spanish, and Mexicans.\(^5\) Whether this is because of underdiagnosis, under-reporting, or low incidence cannot be determined with certainty.

**Mapping of the gene for CHH by linkage and linkage disequilibrium analysis**
Assignment of the CHH gene to the proximal part of 9p was accomplished by a random search for linkage in 14 Finnish families.\(^6\) Subsequently, linkage to the same locus was shown in a large series of Amish families.\(^7\) No signs of heterogeneity within or between the two populations were detected.

As there were no recombinations within the highly polymorphic marker D9S163 (lod score 26:30 at \(\theta = 0\)) CHH could be placed in the vicinity of D9S163 in the 4 cM interval between markers D9S165 and D9S50. As both the Finnish and Amish populations had few founders and have remained highly isolated, it could be assumed that the number of ancestral mutations would be small, possibly with a single
mutation accounting for the majority of the patients in each population. Haplotype analyses and linkage disequilibrium studies confirmed this assumption. Moreover, the strength of linkage disequilibrium was used to assess the distance between D9S163 and CHH by a recently developed method. The current best estimate of this distance is 0-3 cM.

Genetics and penetrance

Genetic studies among Amish and Finnish families have confirmed the recessive mode of inheritance in CHH. However, segregation analyses showed a slightly lower number of affected members than expected according to the recessive hypothesis. This has been explained by reduced penetrance or by the loss of affected children in utero or in infancy. The mapping of CHH and availability of closely linked polymorphic markers provide a tool to examine the question of penetrance. If reduced penetrance were responsible for the unexpectedly low proportion of affected children in CHH sibships, healthy persons with haplotypes identical to their affected sibs should be found. Such a phenomenon was not found in a total of 66 unaffected sibs but was not found.

This finding is indeed credible as reduced penetrance appears to be very rare in recessively inherited disorders. Several other mechanisms might account for the observed under-representation of affected children, which is more pronounced in the Amish than in the Finnish series. The haplotype analyses done in unaffected sibs appear to exclude not only reduced penetrance, but also genetic heterogeneity.

Remaining explanations are uniparental disomy, monosomy owing to deletion, biased ascertainment of families, early lethality in a fraction of homogygotes, and gametic selection.

Prenatal diagnosis

As CHH may in some cases be severe or even fatal, some families with an affected child have requested prenatal testing for CHH. The precise mapping of the CHH gene with respect to several highly polymorphic DNA markers provides an excellent opportunity for accurate predictive testing based on the segregation of those markers in families with a previous history of CHH. Four prenatal determinations have so far been done; in three cases the fetus was predicted to be unaffected, and in one case an affected fetus was predicted. In all cases the outcome was as predicted.

Hypotheses regarding the pathogenesis

The pathogenesis of the disorder remains unknown. However, since previous studies have established defective cellular proliferation of T and B lymphocytes and fibroblasts, and defective erythropoiesis, it is suggested that the clinical manifestations (growth failure, sparse hair, recurrent infections, anaemia, Hirschsprung's disease) in CHH may result from a generalised defect of cellular proliferation. It is intriguing to note that a gene causing isolated Hirschsprung's disease located on chromosome 10 has recently been cloned. It follows that one of the pleiotropic effects of the CHH gene, Hirschsprung's disease, arises either by a different mechanism from that in the isolated form of the disease, or by the interaction of the two genes. Additional studies are needed to elucidate further the molecular mechanisms in the pathogenesis of CHH. The solution will probably have to await the cloning and characterisation of the gene itself.

These studies have been supported by the Academy of Finland, the Sigfrið Juelius Foundation, the March of Dimes Birth Defects Foundation, the Human Growth Foundation, the Olli-Vikki and Sakari Sohlberg Foundation, the Finnish Medical Foundation, the Foundation for Paediatric Research.